Form 8-K - Current report:
SEC Accession No. 0001193125-20-196296
Filing Date
2020-07-21
Accepted
2020-07-21 16:06:02
Documents
19
Period of Report
2020-07-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d68015d8k.htm   iXBRL 8-K 37371
2 EX-4.1 d68015dex41.htm EX-4.1 82292
3 EX-4.2 d68015dex42.htm EX-4.2 84663
4 EX-5.1 d68015dex51.htm EX-5.1 17015
5 EX-10.1 d68015dex101.htm EX-10.1 188002
6 EX-99.1 d68015dex991.htm EX-99.1 11783
10 GRAPHIC g68015g0721013307248.jpg GRAPHIC 1785
11 GRAPHIC g68015g0721031830270.jpg GRAPHIC 2357
  Complete submission text file 0001193125-20-196296.txt   665118

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA onct-20200717.xsd EX-101.SCH 3073
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE onct-20200717_lab.xml EX-101.LAB 18139
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE onct-20200717_pre.xml EX-101.PRE 11410
12 EXTRACTED XBRL INSTANCE DOCUMENT d68015d8k_htm.xml XML 3414
Mailing Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

EIN.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 201038967
SIC: 2834 Pharmaceutical Preparations